4-(3-甲氧基-3-氧代丙基)-3,5-二甲基-1H-吡咯-2-羧酸 | 13219-76-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 4-(3-甲氧基-3-氧代丙基)-3,5-二甲基-1H-吡咯-2-羧酸
• 中文别名: 4-(2-甲酯基-乙基)-3,5-二甲基-1H-吡咯-2-羧酸
• 英文名称: 4-<2-(methoxycarbonyl)ethyl>-3,5-dimethylpyrrole-2-carboxylic acid
• 英文别名: 4-(2-methoxycarbonylethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid；4-(3-methoxy-3-oxopropyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid；3-(2-Methoxycarbonylethyl)-3,5-dimethylpyrrole-2-carboxylic acid；3,5-dimethyl-4-methylcarboxyethylpyrrole-2-carboxylic acid；4-(2-methoxycarbonyl-ethyl)-3,5-dimethyl-pyrrole-2-carboxylic acid；4-(2-methoxycarbonyl-ethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
• CAS: 13219-76-6
• 化学式: C₁₁H₁₅NO₄
• 分子量: 225.244
• InChiKey: BAYZEPRJHFPEIG-UHFFFAOYSA-N

物化性质

• 沸点：
  397.4±42.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(3-甲氧基-3-氧代丙基)-3,5-二甲基-1H-吡咯-2-羧酸 在 哌啶 、 sodium hydroxide 、 sodium acetate 作用下， 以 甲醇 、 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 76.0h， 生成 抗癌医药中间体
  参考文献：
  名称：

  Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

  摘要：

  Receptor tyrosine kinases (RTKs) have been implicated as therapeutic targets for the treatment of human diseases including cancers, inflammatory diseases, cardiovascular diseases including arterial restenosis, and fibrotic diseases of the lung, liver, and kidney. Three classes of 3-substituted indolin-2-ones containing propionic acid functionality attached to the pyrrole ring at the C-3 position of the core have been identified as catalytic inhibitors of the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) RTKs. Some of the compounds were found to inhibit the tyrosine kinase activity associated with isolated vascular endothelial growth factor receptor 2 (VEGF-R2) [fetal liver tyrosine kinase 1 (Flk-1)/kinase insert domain-containing receptor (KDR)], fibroblast growth factor receptor (FGF-R), and platelet-derived growth factor receptor (PDGF-R) tyrosine kinase with IC50 values at nanomolar level. Thus, compound 1 showed inhibition against VEGF-R2 (Flk-1/KDR) and FGF-R1 tyrosine kinase activity With IC50 values of 20 and 30 nM, respectively, while compound 16f inhibited the PDGF-R tyrosine kinase activity with IC50 value of 10 nM. Structural models and structure-activity relationship analysis of these compounds for the target receptors are discussed. The cellular activities of these compounds were profiled using cellular proliferation assays as measured by bromodeoxyuridine (BrdU) incorporation. Specific and potent inhibition of cell growth was observed for some of these compounds. These data provide evidence that these compounds can be used to inhibit the function of these target receptors.

  DOI：

  10.1021/jm9904295
• 作为产物：
  描述：

  5-(苄氧羰基)-2,4-二甲基-3-吡咯丙酸甲酯 在 palladium on activated charcoal 氢气 作用下， 以 丙酮 为溶剂， 生成 4-(3-甲氧基-3-氧代丙基)-3,5-二甲基-1H-吡咯-2-羧酸
  参考文献：
  名称：

  基于硼二吡咯亚甲基发色团的一氧化氮高灵敏度荧光探针潜在有用的生物成像荧光探针的合理设计

  摘要：

  已知硼二吡咯甲烯 (BODIPY) 在水溶液中具有高荧光量子产率 (phi)，但与荧光素相比，在生物应用中的利用并不多。我们开发了 8-(3,4-diaminophenyl)-2,6-bis(2-carboxyethyl)-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s -indacene (DAMBO-P(H))，基于 BODIPY 发色团，作为一氧化氮 (NO) 的高灵敏度荧光探针。DAMBO-P(H) 具有 0.002 的低 phi 值，而其三唑衍生物 (DAMBO-P(H)-T)，即 DAMBO-P(H) 与 NO 反应的产物，发出强烈荧光（phi = 0.74 ）。发现荧光强度的变化受分子内光致电子转移（PeT）机制控制。DAMBO-P(H)的开发策略如下：（1）为了设计高灵敏度的NO探针，

  DOI：

  10.1021/ja037944j

文献信息

• Indolinone compounds as kinase inhibitors
  申请人：Sugen, Inc.

  公开号：US06689806B1

  公开（公告）日：2004-02-10

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.

  这项发明涉及某些吲哚酮化合物，它们的合成方法，以及由该发明的吲哚酮化合物组成的组合式文库。该发明还涉及使用该发明的吲哚酮化合物调节蛋白激酶功能的方法，以及通过调节蛋白激酶功能和相关信号转导途径治疗疾病的方法。
• 5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases
  作者：Naparat Kammasud、Chantana Boonyarat、Kingkan Sanphanya、Maleeruk Utsintong、Satoshi Tsunoda、Hiroaki Sakurai、Ikuo Saiki、Isabelle André、David S. Grierson、Opa Vajragupta

  DOI：10.1016/j.bmcl.2008.12.023

  日期：2009.2

  inhibited the tyrosine phosphorylation in FGF, VEGF, and PDGF receptors and the activation of extracellular signal-regulated kinase (ERK), c-Jun-N-terminal-kinase (JNK) and AKT after the rhFGF-2 stimulation. The introduction of the phenyl hydrazide motif to the position 5 of the pyrido[2,3-d]pyrimidine scaffold led to the inhibitory effect in two signaling pathways: inhibition of AKT activation in the phosphatidyl

  NP506，3- 2,4-二甲基-5- [2-氧代-5-（N'-苯基肼基羰基）-1,2-二氢-吲哚-3-亚甲基] -1 H-吡咯-3-基}通过计算研究，将β-丙酸设计为FGF受体1抑制剂，发现在rhFGF-2刺激后，β-丙酸比SU6668对HUVEC的内皮细胞增殖更具活性，最低有效剂量为10μM。NP506抑制rhFGF-2刺激后FGF，VEGF和PDGF受体中的酪氨酸磷酸化以及细胞外信号调节激酶（ERK），c-Jun-N-末端激酶（JNK）和AKT的激活。将苯基酰肼基序引入吡啶基[2,3- d]的5位]嘧啶支架在两个信号传导途径中产生抑制作用：抑制磷脂酰肌醇3'-激酶（PI13K）/ AKT信号传导途径中的AKT活化，以及抑制MAPK途径中的ERK和JNK活化。
• Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway
  作者：Floriane Gibault、Fabrice Bailly、Matthieu Corvaisier、Mathilde Coevoet、Guillemette Huet、Patricia Melnyk、Philippe Cotelle

  DOI：10.1002/cmdc.201700063

  日期：2017.6.21

  Porphyrin derivatives, in particular verteporfin (VP), a photosensitizer initially designed for cancer therapy, have been identified as inhibitors of the YAP-TEAD interaction and transcriptional activity. Herein we report the efficient convergent synthesis of the dipyrrin half of protoporphyrin IX dimethyl ester (PPIX-DME), in which the sensitive vinyl group was created at the final stage by a dehydroiodination

  卟啉衍生物，特别是verteporfin（VP），一种最初设计用于癌症治疗的光敏剂，已被确定为YAP-TEAD相互作用和转录活性的抑制剂。本文中，我们报告了原卟啉IX二甲基酯（PPIX-DME）的二吡啶半部分的有效收敛合成，其中敏感的乙烯基是在最后阶段通过脱碘化氢反应生成的。合成了另外两种二吡啶衍生物，包括二吡啶19 [（Z）-2-（（（3,5-二甲基-4-乙烯基-2H-吡咯-2-亚烷基）甲基）-3,5-二甲基-4-乙烯基- 1H-吡咯]，含有两个乙烯基。我们发现VP和双嘧啶19在MDA-MB-231人乳腺癌细胞中显示出对TEAD转录活性的显着抑制作用，而其他化合物则没有显示出显着变化。此外，我们观察到VP治疗后YAP和TAZ含量均显着降低，而双吡啶19治疗则主要降低了YAP和受体激酶AXL（YAP的下游靶标）的水平。总之，我们的数据表明，由于卟啉和二吡啶相关的衍生物，由于它们的化学结构，
• Pyrrole-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1568698A1

  公开（公告）日：2005-08-31

  The present invention relates to compounds of the formulae I and Ia, wherein R0 ; R1 ; R2 ; R3 ; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae I and Ia are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ia, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及化合物的公式I和Ia，其中R0; R1; R2; R3; R4; R22，Q; V，G和M具有索赔中指示的含义。公式I和Ia的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，并适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可用于存在因子Xa和/或因子VIIa不良活性或需要抑制因子Xa和/或因子VIIa的治疗或预防的情况。此外，本发明还涉及化合物I和Ia的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• Haem d1: development of a new coupling procedure leading to the synthesis of isobacteriochlorins 1
  作者：Richard L. Mackman、Jason Micklefield、Michael H. Block、Finian J. Leeper、Alan R. Battersby

  DOI：10.1039/a700654c

  日期：——

  A new approach has been developed for construction of the western and eastern lactams, e.g. 2 and 3, needed for synthesis of isobacteriochlorins. It involves acylation of pyrroles with lactonic acids to form ketones. These are then efficiently converted into the desired lactams by a short sequence of reactions. All the steps are high yielding and simple to carry out.

  西部大开发走出一条新路子 和东部内酰胺，例如2和3，合成所需 异细菌二氢卟酚。它涉及吡咯与内酯的酰化 酸形成酮。然后将它们有效地转换为 通过一系列短反应生成所需的内酰胺​​。所有的台阶都很高 产量高且易于实施。